Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme J Hankey

Circulation

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Circulation|February 26, 2019
Antithrombotic Therapy for Stroke PreventionGraeme J Hankey
Circulation|July 20, 2022
Endovascular Therapy for Acute Basilar Artery OcclusionGraeme J Hankey
Circulation|November 29, 2021
Embolic Stroke of Undetermined Source: Can We Identify Subgroups With High Risk for Atrial Fibrillation Who May Benefit From Oral Anticoagulation?Graeme J Hankey
Circulation|April 6, 2011
Dabigatran etexilate: a new oral thrombin inhibitorGraeme J Hankey, John W Eikelboom
Circulation|May 9, 2018
Patent Foramen Ovale Closure: The Pendulum SwingsGraeme J Hankey, Brendan M McQuillan
Circulation|November 17, 2025
Unsuccessful Thrombectomy During Acute Ischemic Stroke: Can it be Rescued by Angioplasty or Stenting?Jan K Ho, Graeme J Hankey
Circulation|October 8, 2008
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular riskJohn W Eikelboom, Graeme J Hankey, Jim Thom, et al.
Circulation|July 13, 2016
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"Jonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Circulation|December 18, 2015
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial FibrillationJonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Circulation|February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Circulation|February 26, 2019
Antithrombotic Therapy for Stroke PreventionGraeme J Hankey
Circulation|July 20, 2022
Endovascular Therapy for Acute Basilar Artery OcclusionGraeme J Hankey
Circulation|November 29, 2021
Embolic Stroke of Undetermined Source: Can We Identify Subgroups With High Risk for Atrial Fibrillation Who May Benefit From Oral Anticoagulation?Graeme J Hankey
Circulation|April 6, 2011
Dabigatran etexilate: a new oral thrombin inhibitorGraeme J Hankey, John W Eikelboom
Circulation|May 9, 2018
Patent Foramen Ovale Closure: The Pendulum SwingsGraeme J Hankey, Brendan M McQuillan
Circulation|November 17, 2025
Unsuccessful Thrombectomy During Acute Ischemic Stroke: Can it be Rescued by Angioplasty or Stenting?Jan K Ho, Graeme J Hankey
Circulation|October 8, 2008
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular riskJohn W Eikelboom, Graeme J Hankey, Jim Thom, et al.
Circulation|July 13, 2016
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"Jonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Circulation|December 18, 2015
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial FibrillationJonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Circulation|February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
Pageof 2